Global Radiation Dermatitis Market Overview:
Radiation Dermatitis is one of the side effects of radiotherapy in the treatment of cancer. Radiation Dermatitis occurs in more than 95% of people who undergo radiation dermatitis. It occurs when radiation therapy damages the outer layer of people’s skin. When hospitals or doctors use X-rays, gamma rays to destroy cancer cells; these rays also make tiny breaks in DNA inside tiny cells to stop it from growing and dividing but this also leads to exposure of these rays to normal rays that get damaged. Radiation Dermatitis has different severity with respect to people. Some individuals experience mild redness while others may experience painful and broken skin. The symptoms of Radiation Dermatitis typically arise after a few weeks or days. Which may include redness or pinkiness of skin, skin swelling, peeling skin, blisters, or skin ulcers. As, radiotherapy is one of the most effective and common methods to treat cancer the radiation dermatitis is very common.
- Growing Prevalence of Cancer Disease and Side Effects Related to the Treatment
- Need of Radiology for The Treatment of Cancer Which Causes Radiation Dermatitis
- Increasing Demand for Alcohol-Free Moisturizer for Applying on Affected Skin
- Lack of Medical Infrastructure in Developing Countries
- Availability of Medical Infrastructure in Developed Countries
- Increasing Spendings of People on the Diagosis
- High Cost Associated with Treating Severe Radiation Dermatitis
With the increasing use of radiotherapy as a treatment for cancer, the demand for radiation dermatitis medication is increasing. The market is fragmented and does not any distinct market leader. There are no major barriers to entry into the market for new entrants but gaining a good reputation could be a challenge. Radiation Dermatitis is good to segment to expand into if some company is already operating in the skincare market.
Some of the key players profiled in the report are 3M Health Care (United States), Charles River Laboratories (United States), Sonoma Pharmaceuticals (United States), ICON PLC. (Ireland), Eurofins Scientific (Luxembourg), Taconic Biosciences (United States), Mölnlycke Health Care AB (Sweden), Smith & Nephew plc (United Kingdom), EVOTEC (United Kingdom), Integra Lifesciences Holdings Corporation (United States) and Intermed S.A. (Greece). Considering Market by Drug Administration, the sub-segment i.e. Oral will boost the Radiation Dermatitis market.
Dec 10, 2020, Sonoma Pharmaceuticals a healthcare leader who also manufactures medication for Radiation Dermatitis and Crown Laboratories, a global skincare company announced that they have entered into a supply agreement for the exclusive rights to sell and market products for the over-the-counter dermatological market in the United States. Both Companies plan to sell a unique variety of formulations to quickly relieve itch and skin irritations.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Radiation Dermatitis market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Radiation Dermatitis market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Radiation Dermatitis Medication Manufacturers, Suppliers, and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations, End-Use Industries and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.